Merck Sharp + Dohme Corp.

University of Texas System

Aimin Tang

Zhifeng Chen

Lan Zhang

Kalpit A Vora

Kara S Cox

Daniel DiStefano

Hua-Poo Su

Tong-Ming Fu

Zhiqiang An

Ningyan Zhang

Dai Wang

Danilo R Casimiro

Daniel C Freed

Sha Ha

Adam C Finnefrock

Fengsheng Li

The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

Antibody neutralizing human respiratory syncytial virus

The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). The antigen binding proteins of the invention are useful as a prophylactic and/or therapeutic agent for preventing and/or treating CMV infections in a patient in need thereof. Also encompassed by the invention are pharmaceutical compositions comprising the antigen binding proteins of the invention and a pharmaceutically acceptable carrier. The invention further relates to methods of using the antigen binding proteins and pharmaceutical compositions of the invention for the prevention or treatment of CMV infection in patients in need thereof.

CMV neutralizing antigen binding proteins

The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.

PD-1 binding proteins

Growing community of inventors

Lansdale, PA, United States of America

Aimin Tang